EGFR and non-small cell lung carcinoma: The LUX-Lung 3 and 6 trial also showed the superiority of afatinib over chemotherapy in patients with EGFR mutation-positive NSCLC and BM (11.1 vs. 5.4 months; HR: 0.54; p = 0.1378) and (8.2 vs. 4.7 months; HR: 0.47; p = 0.1060) [26].